CD4+ T-cell Count Useful to Assess Antiretroviral Therapy Response in HTLV-1/HIV Patients

Article

The authors compared the CD4+ T-cell counts and HIV-1 RNA viral loads of 383 patients who were either mono-infected with HIV or co-infected with HTLV-1/HIV. They confirmed that co-infected patients were more likely to have higher CD4+ T-cell counts prior to treatment initiation with no immunologic benefit--a result that has been well documented in scholarly literature. Any differences in the CD4+ T-cell counts were expected to disappear once the co-infected and mono-infected patients began to fail their antiretroviral therapy (ART) regimens.Instead, the authors found that HTLV-1/HIVco-infected patients continued to have elevated CD4+ T-cell counts, on average 115 cells/μL higher than their HIV mono-infected counterparts, over the two-year study period. But when the authors compared the HIV viral loads over the same period, they could not find any statistically significant difference between the two groups of patients. HIV viral load testing is currently recommended by the World Health Organization (WHO) as an accurate strategy for monitoring a patient's response to ART. Nevertheless, CD4+ T-cell testing is often used in resource-limited settings because it is perceived to be more affordable. The continued use of CD4+ T-cell testing has implications for the clinical management of HIV-positive patients. Results from the present study suggest that HTLV-1/HIV co-infection could delay the identification of patients who are failing ART with adverse consequences.Against this background, recent scientific research has begun to show that HIV viral load testing can be both an accurate and cost-effective treatment monitoring strategy. The present study was based in the KwaZulu-Natal province of South Africa and used patient data from a poor and rural community at the epicenter of the global HIV epidemic.Source: Bentham Science Publishers

Related Videos
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Vaccine conspiracy theory vector illustration word cloud  (Adobe Stock 460719898 by Colored Lights)
Related Content